GluCare.Health, a hybrid digital therapeutics company focused on diabetes, have signed a partnership agreement to launch a value-based weight management pilot with Danish multinational pharmaceutical company, Novo Nordisk.
Set to begin in September 2022, the trial will launch with a150-patient weight management pilot programme in the United Arab Emirates (UAE). The aim of the trial is to study the treatment outcomes of hands-on patient care and data-driven remote care, compared to traditional models practised in the country.
Subject to minimum requirements, GluCare.Health and Novo Nordisk will cover all or a portion of the cost of care, should a participant not lose at least 10% of their body weight by the end of the trial.
Details about legal team TBA